GRITTI, GIUSEPPE
GRITTI, GIUSEPPE
DIPARTIMENTO DI MEDICINA E CHIRURGIA (SCHOOL OF MEDICINE AND SURGERY)
Exposure to obinutuzumab does not affect outcomes of SARS-CoV-2 infection in vaccinated patients with newly diagnosed advanced-stage follicular lymphoma
2024 Pinto, A; Caltagirone, M; Battista, M; Gazzoli, G; Patti, C; Pennese, E; Delorenzo, S; Pavone, V; Merli, M; Chiarenza, A; Gorgone, A; Piazza, F; Puccini, B; Noto, A; Arcaini, L; Defilippi, R; Zinzani, P; Ferreri, A; Ladetto, M; Ferrari, S; Gritti, G
Multidisciplinary and personalized approach to the management of mycosis fungoides with chlormethine gel: a collection of clinical experiences
2024 Violetti, S; Ardigo, M; Fava, P; Gritti, G; Morsia, E; Onida, F; Paulli, M; Pileri, A; Quaglino, P; Rupoli, S; Teoli, M; Vezzoli, P
Polatuzumab vedotin, venetoclax, and an anti-CD20 monoclonal antibody in relapsed/refractory B-cell non-Hodgkin lymphoma
2024 Yuen, S; Phillips, T; Bannerji, R; Marlton, P; Gritti, G; Seymour, J; Johnston, A; Arthur, C; Dodero, A; Sharma, S; Hirata, J; Musick, L; Flowers, C
Predictive model for the risk of cytokine release syndrome with glofitamab treatment for diffuse large B-cell lymphoma
2024 Gritti, G; Belousov, A; Relf, J; Dixon, M; Tandon, M; Komanduri, K
Rapid immune reconstitution following the infusion of autologous, Blinatumomab Expanded T-cells (BET) in patients with B-cell indolent NHL or CLL
2024 Gritti, G; Ferrari, S; Lussana, F; Barbui, A; Landi, F; Rondi, M; Putelli, A; Ballardini, F; Quaresmini, G; Paganessi, M; Pavoni, C; Ghirardi, A; Gotti, E; Capelli, C; Golay, J; Introna, M; Rambaldi, A
Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): a multicentre, open-label, single-arm, phase 2 study
2024 Zinzani, P; Izutsu, K; Mehta-Shah, N; Barta, S; Ishitsuka, K; Cordoba, R; Kusumoto, S; Bachy, E; Cwynarski, K; Gritti, G; Prica, A; Jacobsen, E; Feldman, T; Guillermin, Y; Ennishi, D; Yoon, D; Domenech, E; Zain, J; Wang, J; Kim, J; Poel, M; Jin, J; Wu, S; Chen, Y; Moriyama, T; Inoue, A; Nakajima, K; Horwitz, S
Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: a 3-year follow-up
2023 Zinzani, P; Santoro, A; Gritti, G; Brice, P; Barr, P; Kuruvilla, J; Cunningham, D; Kline, J; Johnson, N; Mehta-Shah, N; Lisano, J; Wen, R; Akyol, A; Moskowitz, A
Spleen tyrosine kinase/FMS-Like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/ CB-659
2023 Gordon, L; Karmali, R; Kaplan, J; Popat, R; Burris, H; Ferrari, S; Madan, S; Patel, M; Gritti, G; El-Sharkawi, D; Chau, F; Radford, J; de Oteyza, J; Zinzani, P; Iyer, S; Townsend, W; Miao, H; Proscurshim, I; Wang, S; Katyayan, S; Yuan, Y; Zhu, J; Stumpo, K; Shou, Y; Carpio, C; Bosch, F
Targeting MCL-1 and BCL-2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non-Hodgkin lymphoma: Results from preclinical models and a Phase Ib study
2023 Lasater, E; Amin, D; Bannerji, R; Mali, R; Barrett, K; Rys, R; Oeh, J; Lin, E; Sterne-Weiler, T; Ingalla, E; Go, M; Yu, S; Krem, M; Arthur, C; Hahn, U; Johnston, A; Karur, V; Khan, N; Marlton, P; Phillips, T; Gritti, G; Seymour, J; Tani, M; Yuen, S; Martin, S; Chang, M; Rose, C; Pham, V; Polson, A; Chang, Y; Wever, C; Johnson, N; Jiang, Y; Hirata, J; Sampath, D; Musick, L; Flowers, C; Wertz, I
Treating relapsed/refractory mature T- and NK-cell neoplasms with tislelizumab: a multicenter open-label phase 2 study
2023 Bachy, E; Savage, K; Huang, H; Kwong, Y; Gritti, G; Zhang, Q; Liberati, A; Cao, J; Yang, H; Hao, S; Hu, J; Zhou, K; Petrini, M; Russo, F; Zhang, H; Sang, W; Ji, J; Ferreri, A; Damaj, G; Liu, H; Zhang, W; Ke, X; Ghiggi, C; Huang, S; Li, X; Yao, H; Paik, J; Novotny, W; Zhou, W; Zhu, H; Zinzani, P
Anti-CCR9 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia
2022 Maciocia, P; Wawrzyniecka, P; Maciocia, N; Burley, A; Karpanasamy, T; Devereaux, S; Hoekx, M; O'Connor, D; Leon, T; Rapoz-D'Silva, T; Pocock, R; Rahman, S; Gritti, G; Yanez, D; Ross, S; Crompton, T; Williams, O; Lee, L; Pule, M; Mansour, M
Autologous stem-cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO/FIL study
2022 Garcia-Sancho, A; Bellei, M; Lopez-Parra, M; Gritti, G; Cortes, M; Novelli, S; Panizo, C; Petrucci, L; Gutierrez, A; Dlouhy, I; Bastos-Oreiro, M; Sancho, J; Ramirez, M; Moraleda, J; Carrillo, E; Jimenez-Ubieto, A; Jarque, I; Orsucci, L; Garcia-Torres, E; Montalban, C; Dodero, A; Arranz, R; de las Heras, N; Pascual, M; Lopez-Jimenez, J; Spina, M; Re, A; de Villambrosia, S; Bobillo, S; Federico, M; Caballero, D
Chimeric antigen receptor T cells for gamma–delta T cell malignancies
2022 Wawrzyniecka, P; Ibrahim, L; Gritti, G; Pule, M; Maciocia, P
DeepMIF: Deep Learning Based Cell Profiling for Multispectral Immunofluorescence Images with Graphical User Interface
2022 Hagos, Y; Akarca, A; Ramsay, A; Rossi, R; Pomplun, S; Moioli, A; Gianatti, A; Mcnamara, C; Rambaldi, A; Quezada, S; Linch, D; Gritti, G; Marafioti, T; Yuan, Y
Generation and validation of a PET radiomics model that predicts survival in diffuse large B cell lymphoma treated with R-CHOP14: A SAKK 38/07 trial post-hoc analysis
2022 Ceriani, L; Milan, L; Cascione, L; Gritti, G; Dalmasso, F; Esposito, F; Pirosa, M; Schar, S; Bruno, A; Dirnhofer, S; Giovanella, L; Hayoz, S; Mamot, C; Rambaldi, A; Chauvie, S; Zucca, E
Genetic and phenotypic attributes of splenic marginal zone lymphoma
2022 Bonfiglio, F; Bruscaggin, A; Guidetti, F; Terzi di Bergamo, L; Faderl, M; Spina, V; Condoluci, A; Bonomini, L; Forestieri, G; Koch, R; Piffaretti, D; Pini, K; Pirosa, M; Cittone, M; Arribas, A; Lucioni, M; Ghilardi, G; Wu, W; Arcaini, L; Baptista, M; Bastidas, G; Bea, S; Boldorini, R; Broccoli, A; Buehler, M; Canzonieri, V; Cascione, L; Ceriani, L; Cogliatti, S; Corradini, P; Derenzini, E; Devizzi, L; Dietrich, S; Elia, A; Facchetti, F; Gaidano, G; Garcia, J; Gerber, B; Ghia, P; Gomes da Silva, M; Gritti, G; Guidetti, A; Hitz, F; Inghirami, G; Ladetto, M; Lopez-Guillermo, A; Lucchini, E; Maiorana, A; Marasca, R; Matutes, E; Meignin, V; Merli, M; Moccia, A; Mollejo, M; Montalban, C; Novak, U; Oscier, D; Passamonti, F; Piazza, F; Pizzolitto, S; Rambaldi, A; Sabattini, E; Salles, G; Santambrogio, E; Scarfo, L; Stathis, A; Stussi, G; Geyer, J; Tapia, G; Tarella, C; Thieblemont, C; Tousseyn, T; Tucci, A; Vanini, G; Visco, C; Vitolo, U; Walewska, R; Zaja, F; Zenz, T; Zinzani, P; Khiabanian, H; Calcinotto, A; Bertoni, F; Bhagat, G; Campo, E; De Leval, L; Dirnhofer, S; Pileri, S; Piris, M; Traverse-Glehen, A; Tzankov, A; Paulli, M; Ponzoni, M; Mazzucchelli, L; Cavalli, F; Zucca, E; Rossi, D
High inter-follicular spatial co-localization of CD8+FOXP3+ with CD4+CD8+ cells predicts favorable outcome in follicular lymphoma
2022 Hagos, Y; Akarca, A; Ramsay, A; Rossi, R; Pomplun, S; Ngai, V; Moioli, A; Gianatti, A; Mcnamara, C; Rambaldi, A; Quezada, S; Linch, D; Gritti, G; Yuan, Y; Marafioti, T
Human inhalable antibody fragments neutralizing SARS-CoV-2 variants for COVID-19 therapy
2022 Minenkova, O; Santapaola, D; Milazzo, F; Anastasi, A; Battistuzzi, G; Chiapparino, C; Rosi, A; Gritti, G; Borleri, G; Rambaldi, A; Dental, C; Viollet, C; Pagano, B; Salvini, L; Marra, E; Luberto, L; Rossi, A; Riccio, A; Merlo Pich, E; Santoro, M; De Santis, R
Correction to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial (Journal of Translational Medicine, (2020), 18, 1, (405), 10.1186/s12967-020-02573-9)
2021 Perrone, F; Piccirillo, M; Ascierto, P; Salvarani, C; Parrella, R; Marata, A; Popoli, P; Ferraris, L; Marrocco-Trischitta, M; Ripamonti, D; Binda, F; Bonfanti, P; Squillace, N; Castelli, F; Muiesan, M; Lichtner, M; Calzetti, C; Salerno, N; Atripaldi, L; Cascella, M; Costantini, M; Dolci, G; Facciolongo, N; Fraganza, F; Massari, M; Montesarchio, V; Mussini, C; Negri, E; Botti, G; Cardone, C; Gargiulo, P; Gravina, A; Schettino, C; Arenare, L; Chiodini, P; Gallo, C; Piccirillo, M; Schettino, C; Gravina, A; Gargiulo, P; Ascierto, P; Vitale, M; Trojaniello, C; Palla, M; Bianchi, A; Botti, G; De Feo, G; Miscio, L; Gallo, C; Chiodiniy, P; Ferraris, L; Marrocco-Trischitta, M; Froldi, M; Menicanti, L; Cuppone, M; Gobbo, G; Baldessari, C; Valenti, V; Castelvecchio, S; Poli, F; Giacomazzi, F; Piccinni, R; Annnunziata, M; Biondi, A; Bussolari, C; Mazzoleni, M; Giachi, A; Filtz, A; Manini, A; Poletti, E; Masserini, F; Conforti, F; Gaudiano, G; Favero, V; Moroni, A; Viva, T; Fancoli, F; Ferrari, D; Niro, D; Resta, M; Ballotta, A; Poli, M; Ranucci, M; Ripamonti, D; Binda, F; Tebaldi, A; Gritti, G; Pasulo, L; Gaglio, L; Del Fabbro, R; Alborghetti, L; Giustinetti, G; Columpsi, P; Cazzaniga, M; Capici, S; Sala, L; Di Sciacca, R; Mosca, G; Pirozzi, M; Muiesan, M
Correction: Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19 (Leukemia, (2021), 35, 9, (2710-2714), 10.1038/s41375-021-01299-x)
2021 Gritti, G; Raimondi, F; Bottazzi, B; Ripamonti, D; Riva, I; Landi, F; Alborghetti, L; Frigeni, M; Damiani, M; Mico, C; Fagiuoli, S; Lorini, F; Gandini, L; Novelli, L; Morgan, J; Owens, B; Kanhai, K; Reljanovic, G; Rizzi, M; Di Marco, F; Mantovani, A; Rambaldi, A